SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development ...

We at Insider Monkey have gone over 817 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of ...

TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel ...

The ENVASARC registration trial is a multi-center, open-label, randomized, non-comparative, parallel cohort study at approximately 25 top cancer centers in the United States. TRACON expects the trial ...

SAN DIEGO, Dec. 20, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...

Maxim Group analyst Jason McCarthy maintained a Buy rating on TRACON Pharmaceuticals (TCON – Research Report) yesterday and set a price target of $1.00. Jason McCarthy has given his Buy rating due to ...

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted ...

TRACON Pharmaceuticals TCON shares are trading lower Thursday morning after the company released the results of a six-month independent data monitoring committee (IDMC) review for the ongoing ENVASARC ...

Shares of Tracon Pharmaceuticals (NASDAQ:TCON) dropped sharply on Wednesday after early data from the company’s pivotal ENVASARC Phase 2 trial for its cancer therapy envafolimab disappointed investors ...

The Dow Jones closed higher by more than 250 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders ...